BioWorld

May 3, 2002

View Archived Issues

AVI Starting Avicine Phase III To Speed Approval Timeline

AVI BioPharma Inc. changed the course for its lead anticancer product, the vaccine Avicine, in an effort to shorten the route toward a possible FDA approval. (BioWorld Today) Read More

Syrrx Enters Deal To Provide Roche With Protein Structures

Read More

Demyelination Is Mycobacterium leprae’s Nerve Killer In Infectious And Neurodegenerative Diseases

Read More

Nyxis Getting Ready To Move Glyxins Family Into The Clinic

Read More

Other News To Note

Read More

Quarterly Earnings Reports

Read More